EQ

Equillium Inc

Add to Watchlist

Advanced Chart

1.100

-0.165(-13.043%)1D

Line

Candle

YTD

High

1.240

Open

1.240

VWAP

1.11

Vol

382.31K

Mkt Cap

67.34M

Low

1.070

Amount

425.65K

EV/EBITDA(TTM)

Total Shares

35.25M

55.85M

EV/OCF(TTM)

P/S(TTM)

2.36

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q4

0.00

-100%

-0.335

+318.75%

0.00

-100%

-0.185

-1950%

0.00

-100%

-0.170

+6.25%

Estimates Revision

The market is revising No Change the revenue expectations for Equillium, Inc. (EQ) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 24.18%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+24.18%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast EQ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EQ is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 1.100

Low

4.00

Averages

4.00

High

4.00

Current: 1.100

Low

4.00

Averages

4.00

High

4.00

Jefferies

Buy

downgrade

$8 -> $4

2025-08-20

Reason

Jefferies

Price Target

$8 -> $4

2025-08-20

downgrade

Buy

Reason

Jefferies lowered the firm's price target on Equillium to $4 from $8 and keeps a Buy rating on the shares. The company's recent $30M financing marks a new chapter as it pivots to a new lead pipeline asset, focused initially on the large commercial opportunity in ulcerative colitis, the analyst tells investors in a research note. The firm finds the pre-clinical data generated encouraging/supporting evidence and looks forward to the first-in-human trial set to start in mid-2026. Jefferies added that it updated its revenue model for EQ504 in moderate to severe UC, leading to the new price target.

Leerink Partners

Thomas Smith

Buy

Hold

Downgrades

$3 → $1

2025-03-28

Reason

Leerink Partners

Thomas Smith

Price Target

$3 → $1

2025-03-28

Downgrades

Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Equillium Inc (EQ.O) is -1.01, compared to its 5-year average forward P/E of -5.41. For a more detailed relative valuation and DCF analysis to assess Equillium Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.41

Current PE

-1.01

Overvalued PE

6.86

Undervalued PE

-17.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.26

Current PS

1.10

Overvalued PS

3.75

Undervalued PS

-1.23

Financials

Annual

Quarterly

FY2025Q2

YoY :

-100.00%

0.00

Total Revenue

FY2025Q2

YoY :

+6128.00%

-6.23M

Operating Profit

FY2025Q2

YoY :

-1326.28%

-5.74M

Net Income after Tax

FY2025Q2

YoY :

-1700.00%

-0.16

EPS - Diluted

FY2025Q2

YoY :

-551.05%

-3.01M

Free Cash Flow

FY2025Q2

YoY :

-100.00%

N/A

Gross Profit Margin - %

FY2025Q2

YoY :

+261.50%

-133.79

FCF Margin - %

FY2025Q2

YoY :

-100.00%

N/A

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

6.5K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

6.5K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

EQ News & Events

Events Timeline

2025-10-06 (ET)

2025-10-06

16:05:27

Equillium Ends Partnership and Licensing Agreement with Biocon

2025-08-04 (ET)

2025-08-04

09:19:07

Equillium announces strategic expansion of cryptocurrency treasury strategy

2025-04-24 (ET)

2025-04-24

13:15:48

Leerink says Equillium's itolizumab news 'disappointing but not surprising'

News

5.0

09-23Newsfilter

NeuraClick Appoints Biotech Expert Daniel M. Bradbury as Advisor for Strategic and Metabolic Programs

2.0

09-23NASDAQ.COM

Biotech Stocks Rally in After-Hours Trading: Cassava, Helius, Werewolf, Aytu, and Equillium Drive Late Gains

2.0

09-03NASDAQ.COM

The 5 Best-Performing Stocks in the Nasdaq Composite for August 2025

People Also Watch

GLXG

Galaxy Payroll Group Ltd

TOMI Environmental Solutions Inc

Sunrise New Energy Co Ltd

FAQ

What is Equillium Inc (EQ) stock price today?

The current price of EQ is 1.1 USD — it has decreased -13.04 % in the last trading day.

EQ

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

EQ News & Events

Events Timeline

News

People Also Watch

FAQ

What is Equillium Inc (EQ) stock price today?

What is Equillium Inc (EQ)'s business?

What is the price predicton of EQ Stock?

What is Equillium Inc (EQ)'s revenue for the last quarter?

What is Equillium Inc (EQ)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Equillium Inc (EQ)'s fundamentals?

How many employees does Equillium Inc (EQ). have?

What is Equillium Inc (EQ) market cap?